Literature DB >> 29563343

Neuropathic pain in a Fabry disease rat model.

James J Miller1, Kazuhiro Aoki2, Francie Moehring3, Carly A Murphy1, Crystal L O'Hara3, Michael Tiemeyer2, Cheryl L Stucky3, Nancy M Dahms1.   

Abstract

Fabry disease, the most common lysosomal storage disease, affects multiple organs and results in a shortened life span. This disease is caused by a deficiency of the lysosomal enzyme α-galactosidase A, which leads to glycosphingolipid accumulation in many cell types. Neuropathic pain is an early and severely debilitating symptom in patients with Fabry disease, but the cellular and molecular mechanisms that cause the pain are unknown. We generated a rat model of Fabry disease, the first nonmouse model to our knowledge. Fabry rats had substantial serum and tissue accumulation of α-galactosyl glycosphingolipids and had pronounced mechanical pain behavior. Additionally, Fabry rat dorsal root ganglia displayed global N-glycan alterations, sensory neurons were laden with inclusions, and sensory neuron somata exhibited prominent sensitization to mechanical force. We found that the cation channel transient receptor potential ankyrin 1 (TRPA1) is sensitized in Fabry rat sensory neurons and that TRPA1 antagonism reversed the behavioral mechanical sensitization. This study points toward TRPA1 as a potentially novel target to treat the pain experienced by patients with Fabry disease.

Entities:  

Keywords:  Genetic diseases; Glycobiology; Neuroscience; Pain

Mesh:

Substances:

Year:  2018        PMID: 29563343      PMCID: PMC5926911          DOI: 10.1172/jci.insight.99171

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  94 in total

1.  Genome-wide scanning with SSLPs in the rat.

Authors:  Carol Moreno; Kathleen Kennedy; Jaime Wendt Andrae; Howard J Jacob
Journal:  Methods Mol Med       Date:  2005

2.  Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels.

Authors:  Bertrand Coste; Jayanti Mathur; Manuela Schmidt; Taryn J Earley; Sanjeev Ranade; Matt J Petrus; Adrienne E Dubin; Ardem Patapoutian
Journal:  Science       Date:  2010-09-02       Impact factor: 47.728

3.  Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.

Authors:  Anette Torvin Møller; Flemming Winther Bach; Ulla Feldt-Rasmussen; Ase Rasmussen; Lis Hasholt; He Lan; Claudia Sommer; Steen Kølvraa; Martin Ballegaard; Troels Staehelin Jensen
Journal:  Pain       Date:  2009-08-07       Impact factor: 6.961

4.  A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.

Authors:  C M Eng; M Banikazemi; R E Gordon; M Goldman; R Phelps; L Kim; A Gass; J Winston; S Dikman; J T Fallon; S Brodie; C B Stacy; D Mehta; R Parsons; K Norton; M O'Callaghan; R J Desnick
Journal:  Am J Hum Genet       Date:  2001-02-01       Impact factor: 11.025

5.  Enhancement of GABAA receptor-mediated conductances induced by nerve injury in a subclass of sensory neurons.

Authors:  A A Oyelese; D L Eng; G B Richerson; J D Kocsis
Journal:  J Neurophysiol       Date:  1995-08       Impact factor: 2.714

6.  The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain.

Authors:  Katharine M Walker; Laszlo Urban; Stephen J Medhurst; Sadhana Patel; Mohanjit Panesar; Alyson J Fox; Peter McIntyre
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

7.  Contribution of transient receptor potential ankyrin 1 to chronic pain in aged mice with complete Freund's adjuvant-induced arthritis.

Authors:  Sheldon R Garrison; Cheryl L Stucky
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

8.  Evidence for the role of lipid rafts and sphingomyelin in Ca2+-gating of Transient Receptor Potential channels in trigeminal sensory neurons and peripheral nerve terminals.

Authors:  Éva Sághy; Éva Szőke; Maja Payrits; Zsuzsanna Helyes; Rita Börzsei; János Erostyák; Tibor Zoltán Jánosi; György Sétáló; János Szolcsányi
Journal:  Pharmacol Res       Date:  2015-07-31       Impact factor: 7.658

9.  Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study.

Authors:  Nurcan Üçeyler; Ann-Kathrin Kahn; Daniela Kramer; Daniel Zeller; Jordi Casanova-Molla; Christoph Wanner; Frank Weidemann; Zaza Katsarava; Claudia Sommer
Journal:  BMC Neurol       Date:  2013-05-24       Impact factor: 2.474

10.  Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment.

Authors:  Juan M Politei; Didier Bouhassira; Dominique P Germain; Cyril Goizet; Antonio Guerrero-Sola; Max J Hilz; Elspeth J Hutton; Amel Karaa; Rocco Liguori; Nurcan Üçeyler; Lonnie K Zeltzer; Alessandro Burlina
Journal:  CNS Neurosci Ther       Date:  2016-03-28       Impact factor: 5.243

View more
  23 in total

1.  Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.

Authors:  Xuling Zhu; Ling Yin; Matt Theisen; Jenny Zhuo; Summar Siddiqui; Becca Levy; Vladimir Presnyak; Andrea Frassetto; Jaclyn Milton; Timothy Salerno; Kerry E Benenato; Joe Milano; Andy Lynn; Staci Sabnis; Kristine Burke; Gilles Besin; Christine M Lukacs; Lin T Guey; Patrick F Finn; Paolo G V Martini
Journal:  Am J Hum Genet       Date:  2019-03-14       Impact factor: 11.025

2.  Studying Independent Kcna6 Knock-out Mice Reveals Toxicity of Exogenous LacZ to Central Nociceptor Terminals and Differential Effects of Kv1.6 on Acute and Neuropathic Pain Sensation.

Authors:  Liam J Peck; Ryan Patel; Paula Diaz; Yolanda M Wintle; Anthony H Dickenson; Andrew J Todd; Margarita Calvo; David L H Bennett
Journal:  J Neurosci       Date:  2021-09-20       Impact factor: 6.167

3.  Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model.

Authors:  Siamak Jabbarzadeh-Tabrizi; Michel Boutin; Taniqua S Day; Mouna Taroua; Raphael Schiffmann; Christiane Auray-Blais; Jin-Song Shen
Journal:  J Lipid Res       Date:  2020-08-31       Impact factor: 5.922

Review 4.  Rat models of human diseases and related phenotypes: a systematic inventory of the causative genes.

Authors:  Claude Szpirer
Journal:  J Biomed Sci       Date:  2020-08-02       Impact factor: 8.410

Review 5.  Progress in the understanding and treatment of Fabry disease.

Authors:  James J Miller; Adam J Kanack; Nancy M Dahms
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-09-14       Impact factor: 3.770

Review 6.  Ion channels and pain in Fabry disease.

Authors:  Carina Weissmann; Adriana A Albanese; Natalia E Contreras; María N Gobetto; Libia C Salinas Castellanos; Osvaldo D Uchitel
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

Review 7.  Cutaneous pain in disorders affecting peripheral nerves.

Authors:  Cheryl L Stucky; Alexander R Mikesell
Journal:  Neurosci Lett       Date:  2021-10-01       Impact factor: 3.046

8.  Characterization of small fiber pathology in a mouse model of Fabry disease.

Authors:  Lukas Hofmann; Dorothea Hose; Anne Grießhammer; Robert Blum; Frank Döring; Sulayman Dib-Hajj; Stephen Waxman; Claudia Sommer; Erhard Wischmeyer; Nurcan Üçeyler
Journal:  Elife       Date:  2018-10-17       Impact factor: 8.140

9.  Platelet and myeloid cell phenotypes in a rat model of Fabry disease.

Authors:  Adam J Kanack; Kazuhiro Aoki; Michael Tiemeyer; Nancy M Dahms
Journal:  FASEB J       Date:  2021-08       Impact factor: 5.834

10.  Urine-derived cells: a promising diagnostic tool in Fabry disease patients.

Authors:  Gisela G Slaats; Fabian Braun; Martin Hoehne; Laura E Frech; Linda Blomberg; Thomas Benzing; Bernhard Schermer; Markus M Rinschen; Christine E Kurschat
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.